Drug Trial Radar · NCT07686367
Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Jan 19, 2027
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jul 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and myxoid/round cell liposarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Brenetafusp (IMC-F106C) is in a new class of immunotherapy called immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC). Brenetafusp (IMC-F106C), may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Conditions
- Metastatic Myxoid Liposarcoma
- Metastatic Synovial Sarcoma
- Unresectable Myxoid Liposarcoma
- Unresectable Synovial Sarcoma
Interventions
Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106CBiological
Given IV
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT
Magnetic Resonance ImagingProcedure
Undergo MRI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rateTime frame: Up to 8 cycles (Cycle length = 21 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.